Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The ability of bacteria and viruses to selectively replicate in tumors has led to synthetic engineering of new microbial therapies. Here we design a cooperative strategy whereby bacteria transcribe and deliver the Senecavirus A RNA genome inside host cells, launching a potent oncolytic viral infection. "Encapsidated" by bacteria, the viral genome can further bypass circulating antiviral antibodies to reach the tumor and initiate replication and spread within immune mice. Finally, we engineer the virus to require a bacterially delivered protease to achieve virion maturation, demonstrating bacterial control over the virus. This work extends bacterially delivered therapeutics to viral genomes, and shows how a consortium of microbes can achieve a cooperative aim.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557668 | PMC |
| http://dx.doi.org/10.1101/2023.09.28.559873 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
AAV2 delivery of the gene results in presentation of an HLA-A02:01-restricted T cell epitope potent to induce T cell cytotoxicity.
Mol Ther Methods Clin Dev
September 2025
Office of Gene Therapy, Office of Therapeutic Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA.
genome editing with CRISPR-Cas9 systems is generating worldwide attention and enthusiasm for the possible treatment of genetic disorders. However, the consequences of potential immunogenicity of the bacterial Cas9 protein and the AAV capsid have been the subject of considerable debate. Here, we model the antigen presentation in cells after gene editing by transduction of a human cell line with an AAV2 vector that delivers the Cas9 transgene.
View Article and Find Full Text PDFMetataxonomic and bacterial culture studies of breast milk microbiota in mothers of premature infants: factors influencing its bacterial composition and diversity.
J Nutr
September 2025
Université Paris-Saclay, CEA, Centre National de Recherche en Génomique Humaine (CNRGH), 91057 Evry, France. Electronic address:
Background: Breast milk represents the optimal feeding strategy for newborns, supporting not only nutrition but also the establishment of a unique microbiota. The bacterial composition and diversity of this microbiota are shaped by various maternal and infant-related factors.
Objectives: This single-center prospective study aimed to examine the breast milk microbiota and determine the maternal and infant-related factors influencing its composition and diversity over the time.
Woody Host-Specific Type III Effector HopBL2 Is Essential for Pseudomonas savastanoi Virulence and Associates With Plasmodesmata.
Mol Plant Pathol
September 2025
Área de Genética, Facultad de Ciencias, Campus Teatinos s/n, Universidad de Málaga, Málaga, Spain.
The type III secretion system in Pseudomonas syringae complex pathogens delivers type III effectors (T3Es) into plant cells to manipulate host processes, enhance survival, and promote disease. While substantial research has focused on herbaceous pathogens, T3Es in strains infecting woody hosts are less understood. This study investigates the HopBL family of effectors in Pseudomonas savastanoi, a pathogen of woody plants.
View Article and Find Full Text PDFSingle-cell analysis of genetically minimized Salmonella reveals effector gene cooperation in vivo.
Nat Microbiol
September 2025
Department of Microbiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Bacterial pathogens such as Salmonella Typhimurium (S.Tm) can deliver large repertoires of effector proteins directly into host cells. Due to the genetic and functional redundancies found in these systems, it has been difficult to determine how individual effector proteins cooperate with one another to elicit pathogenic phenotypes in vivo.
View Article and Find Full Text PDFInternational Network of Antibiotic Allergy Nations (iNAAN): Protocol for a type 2 hybrid effectiveness-implementation multicentre prospective cohort and target trial emulation study evaluating penicillin allergy delabeling via direct oral challenge.
PLoS One
September 2025
Department of Infectious Diseases, at the Peter Doherty Institute for Infection and Immunology, Melbourne Medical School, University of Melbourne, Melbourne, Victoria, Australia.
Background: Penicillin allergies are reported in 1 in 10 hospitalised patients globally and are associated with inferior patient and health service outcomes. However, more than 95% of low-risk penicillin allergies can be removed by direct oral challenge (DOC).
Objective: The International Network of Antibiotic Allergy Nations (iNAAN) aims to evaluate the utility of an audit and feedback (A&F) and education implementation strategy to increase the adoption of penicillin DOC in patients with a low-risk penicillin allergy, while concurrently assessing the impact of penicillin DOC on antibiotic prescribing and health service outcomes.